Germline TP53 c.566C>T mutation incidentally diagnosed during treatment for acute myeloid leukemia: A case report
Hiroshi Sato, Seiki Matsuo, Yukiko Ando and 2 more
Clinical Case Reports · 2021
doi:10.1002/ccr3.5221 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract TP53 mutations in acute myeloid leukemia (AML) are associated with poor outcomes. The number of somatic and/or germline genetic tests for therapy is increasing. Patients with such incidental findings should undergo adequate genetic counseling.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.